[HTML][HTML] Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor

T Ueda, K Tsuji, H Yoshino, Y Ebihara… - The Journal of …, 2000 - Am Soc Clin Investig
T Ueda, K Tsuji, H Yoshino, Y Ebihara, H Yagasaki, H Hisakawa, T Mitsui, A Manabe
The Journal of clinical investigation, 2000Am Soc Clin Investig
Here, we demonstrate a significant ex vivo expansion of human hematopoietic stem cells
capable of repopulating in NOD/SCID mice. Using a combination of stem cell factor (SCF),
Flk2/Flt3 ligand (FL), thrombopoietin (TPO), and a complex of IL-6 and soluble IL-6 receptor
(IL-6/sIL-6R), we cultured cord blood CD34+ cells for 7 days and transplanted these cells
into NOD/SCID mice. Bone marrow engraftment was judged successful when recipient
animals contained measurable numbers of human CD45+ cells 10–12 weeks after …
Here, we demonstrate a significant ex vivo expansion of human hematopoietic stem cells capable of repopulating in NOD/SCID mice. Using a combination of stem cell factor (SCF), Flk2/Flt3 ligand (FL), thrombopoietin (TPO), and a complex of IL-6 and soluble IL-6 receptor (IL-6/sIL-6R), we cultured cord blood CD34+ cells for 7 days and transplanted these cells into NOD/SCID mice. Bone marrow engraftment was judged successful when recipient animals contained measurable numbers of human CD45+ cells 10–12 weeks after transplantation. When cells were cultured with SCF+FL+TPO+IL-6/sIL-6R, 13 of 16 recipients were successfully engrafted, and CD45+ cells represented 11.5% of bone marrow cells in engrafted recipients. Cells cultured with a subset of these factors were less efficiently engrafted, both as measured by frequency of successful transplantations and prevalence of CD45+ cells. In animals receiving cells cultured with all 4 factors, human CD45+ cells represented various lineages, including a large number of CD34+ cells. The proportion of CD45+ cells in recipient marrow was 10 times higher in animals receiving these cultured cells than in those receiving comparable numbers of fresh CD34+ cells, and the expansion rate was estimated at 4.2-fold by a limiting dilution method. Addition of IL-3 to the cytokine combination abrogated the repopulating ability of the expanded cells. The present study may provide a novel culture method for the expansion of human transplantable hematopoietic stem cells suitable for clinical applications.
The Journal of Clinical Investigation